BRPI0817293A2 - Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese - Google Patents

Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese

Info

Publication number
BRPI0817293A2
BRPI0817293A2 BRPI0817293-5A BRPI0817293A BRPI0817293A2 BR PI0817293 A2 BRPI0817293 A2 BR PI0817293A2 BR PI0817293 A BRPI0817293 A BR PI0817293A BR PI0817293 A2 BRPI0817293 A2 BR PI0817293A2
Authority
BR
Brazil
Prior art keywords
benzoquinone
angiogenesis
cancer
derivative
treatment
Prior art date
Application number
BRPI0817293-5A
Other languages
English (en)
Inventor
Mark R Kelley
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of BRPI0817293A2 publication Critical patent/BRPI0817293A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0817293-5A 2007-09-26 2008-09-22 Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese BRPI0817293A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97539607P 2007-09-26 2007-09-26
US98956607P 2007-11-21 2007-11-21
PCT/US2008/077210 WO2009042542A1 (en) 2007-09-26 2008-09-22 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis

Publications (1)

Publication Number Publication Date
BRPI0817293A2 true BRPI0817293A2 (pt) 2015-06-16

Family

ID=39951652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817293-5A BRPI0817293A2 (pt) 2007-09-26 2008-09-22 Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese

Country Status (13)

Country Link
US (6) US9089605B2 (pt)
EP (4) EP3725309B1 (pt)
JP (4) JP5628674B2 (pt)
KR (2) KR101572688B1 (pt)
AU (5) AU2008304619C1 (pt)
BR (1) BRPI0817293A2 (pt)
CA (2) CA2700365C (pt)
ES (2) ES2675951T3 (pt)
IL (1) IL204675A0 (pt)
MX (1) MX2010003315A (pt)
RU (1) RU2510270C2 (pt)
WO (2) WO2009042544A1 (pt)
ZA (1) ZA201002246B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089605B2 (en) 2007-09-26 2015-07-28 Indiana University Research And Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
WO2012058635A1 (en) 2010-10-29 2012-05-03 Life Technologies Corporation Biotin derivatives
WO2012145653A2 (en) * 2011-04-22 2012-10-26 University Of Florida Research Foundation Inc. Therapeutic combinations for use in neoplasia
BR112013030370A2 (pt) * 2011-05-26 2017-08-08 Apex Therapeutics Inc compostos de quinona para tratamento de doenças mediadas por ape1
US20140128398A1 (en) 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
WO2013021953A1 (ja) * 2011-08-05 2013-02-14 帝人株式会社 縮合多環芳香族化合物、芳香族重合体、及び芳香族化合物の合成方法
WO2013116228A1 (en) * 2012-01-31 2013-08-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibition of ap endonuclease-1/ redox factor-1 (hape1) activity
CN109602734A (zh) * 2012-03-14 2019-04-12 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
KR101968235B1 (ko) 2012-05-30 2019-04-11 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
KR102212172B1 (ko) 2012-07-09 2021-02-03 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 광학 이방체, 및 중합성 화합물의 제조 방법
WO2014065243A1 (ja) 2012-10-22 2014-05-01 日本ゼオン株式会社 位相差板、円偏光板、及び画像表示装置
US10273322B2 (en) 2013-08-22 2019-04-30 Zeon Corporation Polymerizable compound, polymerizable composition, polymer, and optical anisotropic body
CN105745233B (zh) 2013-10-31 2018-06-12 日本瑞翁株式会社 聚合性化合物、聚合性组合物、高分子、及光学各向异性体
KR101612097B1 (ko) 2015-01-07 2016-04-12 충남대학교산학협력단 아세틸화된 산화환원조절단백-1의 제조방법 및 이를 함유하는 유방암 예방 및 치료용 조성물
US10533137B2 (en) 2015-03-19 2020-01-14 Zeon Corporation Liquid crystal composition, method for producing retardation layer, and circularly polarizing plate
JP6862355B2 (ja) 2015-05-21 2021-04-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 低酸素シグナリング遺伝子を阻害するためにＡＰＥ１／Ｒｅｆ−１を標的とする方法
EP3306364A4 (en) 2015-05-28 2019-01-23 Zeon Corporation CIRCULAR POLARIZATION LIGHT SEPARATING FILM AND METHOD FOR MANUFACTURING THE SAME
KR20170052345A (ko) * 2015-11-04 2017-05-12 충남대학교산학협력단 환원형 산화환원조절단백-1를 함유하는 염증 예방 및 치료용 약학 조성물
JPWO2017110638A1 (ja) 2015-12-22 2018-10-11 日本ゼオン株式会社 液晶性組成物、液晶硬化層及びその製造方法、並びに、光学フィルム
CN109072082A (zh) 2016-03-08 2018-12-21 日本瑞翁株式会社 液晶性组合物、液晶固化层及该液晶固化层的制造方法
US20190350885A1 (en) * 2017-01-25 2019-11-21 Indiana University Research And Technology Corporation Prophylaxis treatment for acute myeloid leukemia
JP2020514349A (ja) * 2017-03-20 2020-05-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用
KR20190128643A (ko) 2017-03-24 2019-11-18 니폰 제온 가부시키가이샤 액정 경화 필름 및 그 제조 방법
WO2018173778A1 (ja) 2017-03-24 2018-09-27 日本ゼオン株式会社 液晶組成物、液晶硬化フィルム及びその製造方法
US20190117602A1 (en) 2017-04-17 2019-04-25 Indiana University Research And Technology Corporation Prevention and reversal of inflammation induced dna damage
WO2018232238A1 (en) * 2017-06-16 2018-12-20 Indiana University Research And Technology Corporation Therapeutic agent for tuberous sclerosis complex (tsc)
WO2019157163A1 (en) * 2018-02-08 2019-08-15 Indiana University Research And Technology Corporation Targeting ocular diseases with novel ape1/ref-1 inhibitors
CN108440271A (zh) * 2018-04-03 2018-08-24 中山大学 一种6-甲氧基萘嵌苯酮类化合物的制备方法
AU2019406461A1 (en) * 2018-12-17 2021-07-01 Indiana University Research And Technology Corporation Treatment of gastrointestinal disorders and symptoms thereof
CN117500492A (zh) * 2021-04-30 2024-02-02 奥库菲尔制药股份有限公司 用于治疗糖尿病视网膜病变和相关病症的方法和组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438998A (en) * 1964-10-05 1969-04-15 Research Corp Antibiotic lambertellin and method for production
JPS51128932A (en) * 1975-04-30 1976-11-10 Takeda Chem Ind Ltd Organic compounds
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
FI102273B1 (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
JPH07291859A (ja) * 1994-04-28 1995-11-07 Eisai Co Ltd 転写因子活性阻害剤
US6406917B1 (en) * 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
AU3386597A (en) * 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
EP0813866A3 (en) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutic agent for joint diseases
FR2757860B1 (fr) * 1996-12-27 1999-04-23 Oxis International Sa Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques
US5849793A (en) * 1997-08-15 1998-12-15 The Picower Institute For Medical Research HIV matrix protein tyrosine position 29 pocket binders
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
ES2231685T3 (es) * 2001-04-05 2005-05-16 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones vasculares diabeticas y relacionadas con la edad.
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
US9089605B2 (en) 2007-09-26 2015-07-28 Indiana University Research And Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
AU2017203131C1 (en) 2020-06-04
US20100297113A1 (en) 2010-11-25
US20150265564A1 (en) 2015-09-24
AU2017203131B2 (en) 2018-08-02
JP2015017091A (ja) 2015-01-29
RU2510270C2 (ru) 2014-03-27
EP3725309B1 (en) 2022-11-23
AU2017203131A1 (en) 2017-06-01
ZA201002246B (en) 2016-02-24
AU2018256605B2 (en) 2019-10-31
US9040505B2 (en) 2015-05-26
CA2700365C (en) 2016-07-05
EP2203161B1 (en) 2018-05-09
US9089605B2 (en) 2015-07-28
US10058523B2 (en) 2018-08-28
EP2203162B1 (en) 2017-11-08
WO2009042542A1 (en) 2009-04-02
EP2203161A1 (en) 2010-07-07
AU2018256605A1 (en) 2018-11-22
ES2653855T3 (es) 2018-02-09
AU2020200585A1 (en) 2020-02-13
US20220184016A1 (en) 2022-06-16
KR20150038712A (ko) 2015-04-08
KR101572688B1 (ko) 2015-11-27
AU2008304619A1 (en) 2009-04-02
AU2015268612A1 (en) 2016-01-07
AU2008304619B2 (en) 2015-09-24
MX2010003315A (es) 2011-03-15
IL204675A0 (en) 2010-11-30
AU2008304619C1 (en) 2020-06-04
RU2010113569A (ru) 2011-11-10
US20100285008A1 (en) 2010-11-11
CA2700274A1 (en) 2009-04-02
JP5628674B2 (ja) 2014-11-19
US20180325853A1 (en) 2018-11-15
JP5646327B2 (ja) 2014-12-24
AU2018256605C1 (en) 2020-07-02
JP2015212293A (ja) 2015-11-26
EP2203162A1 (en) 2010-07-07
KR101689796B1 (ko) 2016-12-27
AU2015268612B2 (en) 2017-02-23
CA2700365A1 (en) 2009-04-02
EP3299015A1 (en) 2018-03-28
ES2675951T3 (es) 2018-07-13
JP2010540545A (ja) 2010-12-24
KR20100084522A (ko) 2010-07-26
US20190231728A1 (en) 2019-08-01
WO2009042544A1 (en) 2009-04-02
JP2010540544A (ja) 2010-12-24
EP3725309A1 (en) 2020-10-21
CA2700274C (en) 2017-08-22

Similar Documents

Publication Publication Date Title
BRPI0817293A2 (pt) Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
IL200193A0 (en) Combination of lbh589 with other therapeutic agents for treating cancer
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
PL2012872T3 (pl) Leczenia nowotworu z użyciem pól elektromagnetycznych w połączeniu z lekami przeciwnowotworowymi
BR112012004149A2 (pt) terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
EP2136846A4 (en) THERAPEUTIC OBJECTIVES AND MOLECULES
ZA200904860B (en) Combination therapy with angiogenesis inhibitors
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
BRPI0919857A2 (pt) tratamentos para cancer com radiacao e imunocitocinas
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0815726A2 (pt) terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0815330A2 (pt) métodos e composições para tratar cânceres
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
BRPI0812924A2 (pt) Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements